What is the new lung cancer treatment approved by NICE?

The new treatment approved by NICE is Amivantamab combined with lazertinib for specific cases of advanced lung cancer.

Who will benefit from Amivantamab with lazertinib on the NHS?

Hundreds of patients in England with untreated EGFR mutation-positive advanced non-small-cell lung cancer will benefit.

Why was the NICE guidance on Amivantamab and lazertinib changed?

NICE changed its guidance after further clinical trial evidence showed the drug increases progression-free survival and overall survival.

Home / Health / New Lung Cancer Drug Gets NHS Green Light

New Lung Cancer Drug Gets NHS Green Light

22 Jan

•

Summary

A new lung cancer treatment is now available on the NHS.
The drug Amivantamab with lazertinib treats advanced lung cancer.
Hundreds of UK patients are expected to benefit from this therapy.

New Lung Cancer Drug Gets NHS Green Light

Amivantamab with lazertinib has been approved for routine use on the NHS in England, offering a new treatment option for hundreds of patients with advanced lung cancer.

Initially, draft guidance from NICE in July 2025 indicated the drug should not be used routinely, citing a lack of evidence for its value for money. However, following a consultation period, NICE has now published final guidance recommending the combination therapy.

Clinical trial evidence presented during the consultation demonstrated that Amivantamab plus lazertinib can increase the time before a patient's condition deteriorates and may extend overall survival compared to other available treatments.

The Medicines and Healthcare products Regulatory Agency had previously approved lazertinib with amivantamab in March 2025. This new availability ensures patients in England will have access to the treatment within 90 days of the final guidance publication.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.